{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:21:26Z","timestamp":1780392086826,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03365-y","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:11:53Z","timestamp":1774307513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of In Situ Gelling Liquid Extended Release System for Oral Delivery of Abiraterone Acetate"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0917-6658","authenticated-orcid":false,"given":"Mohamed M.","family":"Shehata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-9174","authenticated-orcid":false,"given":"Mona F.","family":"Arafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6104","authenticated-orcid":false,"given":"Ahmed E.","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-710X","authenticated-orcid":false,"given":"Gamal M.","family":"El Maghraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"3","key":"3365_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3365_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.eururo.2009.06.027","volume":"56","author":"KN Chi","year":"2009","unstructured":"Chi KN, Bjartell A, Dearnaley D, Saad F, Schr\u00f6der FH, Sternberg C, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56(4):594\u2013605. https:\/\/doi.org\/10.1016\/j.eururo.2009.06.027.","journal-title":"Eur Urol"},{"issue":"3","key":"3365_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/j.seminoncol.2013.04.001","volume":"40","author":"R Schrecengost","year":"2013","unstructured":"Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 2013;40(3):244\u201358. https:\/\/doi.org\/10.1053\/j.seminoncol.2013.04.001.","journal-title":"Semin Oncol"},{"issue":"1","key":"3365_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/cancers15010281","volume":"15","author":"V Tzelepi","year":"2022","unstructured":"Tzelepi V. Prostate cancer: pathophysiology, pathology and therapy. Cancers. 2022;15(1):281. https:\/\/doi.org\/10.3390\/cancers15010281.","journal-title":"Cancers"},{"issue":"24","key":"3365_CR5","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-13-2134","volume":"19","author":"PG Kluetz","year":"2013","unstructured":"Kluetz PG, Ning YM, Maher VE, Zhang L, Tang S, Ghosh D, et al. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: US food and drug administration drug approval summary. Clin Cancer Res. 2013;19(24):6650\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2134.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3365_CR6","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1078-0432.CCR-11-1805","volume":"18","author":"MN Stein","year":"2012","unstructured":"Stein MN, Goodin S, DiPaola RS. Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res. 2012;18(7):1848\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1805.","journal-title":"Clin Cancer Res"},{"key":"3365_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/B978-0-12-396521-9.00011-5","volume":"1","author":"Q Hu","year":"2014","unstructured":"Hu Q, Hartmann RW. The renaissance of CYP17 inhibitors for the treatment of prostate cancer. Cancer Drug Des Discov. 2014;1:319\u201356. https:\/\/doi.org\/10.1016\/B978-0-12-396521-9.00011-5.","journal-title":"Cancer Drug Des Discov"},{"key":"3365_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/CMAR.S39318","volume":"6","author":"EA Mostaghel","year":"2014","unstructured":"Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res. 2014;6:39\u201351. https:\/\/doi.org\/10.2147\/CMAR.S39318.","journal-title":"Cancer Manag Res"},{"key":"3365_CR9","doi-asserted-by":"publisher","first-page":"119069","DOI":"10.1016\/j.ijpharm.2020.119069","volume":"577","author":"HB Schultz","year":"2020","unstructured":"Schultz HB, Meola TR, Thomas N, Prestidge CA. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. Int J Pharm. 2020;577:119069. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119069.","journal-title":"Int J Pharm"},{"key":"3365_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejpb.2020.04.005","volume":"151","author":"T Boleslavsk\u00e1","year":"2020","unstructured":"Boleslavsk\u00e1 T, Sv\u011btl\u00edk S, \u017dv\u00e1tora P, Bos\u00e1k J, Dammer O, Ber\u00e1nek J, et al. Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation. Eur J Pharm Biopharm. 2020;151:81\u201390. https:\/\/doi.org\/10.1016\/j.ejpb.2020.04.005.","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"3365_CR11","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/jcph.564","volume":"55","author":"KN Chi","year":"2015","unstructured":"Chi KN, Spratlin J, Kollmannsberger C, North S, Pankras C, Gonzalez M, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration\u2010resistant prostate cancer. J Clin Pharmacol. 2015;55(12):1406\u201314. https:\/\/doi.org\/10.1002\/jcph.564.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"3365_CR12","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1016\/j.xphs.2016.03.008","volume":"105","author":"S Geboers","year":"2016","unstructured":"Geboers S, Stappaerts J, Mols R, Snoeys J, Tack J, Annaert P, et al. The effect of food on the intraluminal behavior of abiraterone acetate in man. J Pharm Sci. 2016;105(9):2974\u201381. https:\/\/doi.org\/10.1016\/j.xphs.2016.03.008.","journal-title":"J Pharm Sci"},{"issue":"5","key":"3365_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/pharmaceutics14050952","volume":"14","author":"M Braeckmans","year":"2022","unstructured":"Braeckmans M, Augustijns P, Mols R, Servais C, Brouwers J. Investigating the mechanisms behind the positive food effect of abiraterone acetate: in vitro and rat in situ studies. Pharmaceutics. 2022;14(5):952. https:\/\/doi.org\/10.3390\/pharmaceutics14050952.","journal-title":"Pharmaceutics"},{"key":"3365_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","volume":"3","author":"J Rautio","year":"2008","unstructured":"Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, J\u00e4rvinen T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discovery. 2008;3:255\u201370. https:\/\/doi.org\/10.1038\/nrd2468.","journal-title":"Nat Rev Drug Discovery"},{"key":"3365_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2015.01.001","volume":"90","author":"J Stappaerts","year":"2015","unstructured":"Stappaerts J, Geboers S, Snoeys J, Brouwers J, Tack J, Annaert P, et al. Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies. Eur J Pharm Biopharm. 2015;90:1\u20137. https:\/\/doi.org\/10.1016\/j.ejpb.2015.01.001.","journal-title":"Eur J Pharm Biopharm"},{"key":"3365_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119896","volume":"284","author":"Y Sakai","year":"2021","unstructured":"Sakai Y, Fukami T, Nagaoka M, Hirosawa K, Ichida H, Sato R, et al. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. Life Sci. 2021;284: 119896. https:\/\/doi.org\/10.1016\/j.lfs.2021.119896.","journal-title":"Life Sci"},{"issue":"8","key":"3365_CR17","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1021\/acs.cgd.0c00153","volume":"20","author":"R Chennuru","year":"2020","unstructured":"Chennuru R, Devarapalli R, Rengaraj P, Srinivas PL, Dey S, Reddy CM. Improving solubility of poorly soluble abiraterone acetate by cocrystal design aided by in silico screening. Cryst Growth Des. 2020;20(8):5018\u201330. https:\/\/doi.org\/10.1021\/acs.cgd.0c00153.","journal-title":"Cryst Growth Des"},{"key":"3365_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121460","volume":"614","author":"Z Yang","year":"2022","unstructured":"Yang Z, Yang Y, Xia M, Dai W, Zhu B, Mei X. Improving the dissolution behaviors and bioavailability of abiraterone acetate via multicomponent crystal forms. Int J Pharm. 2022;614: 121460. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121460.","journal-title":"Int J Pharm"},{"issue":"9","key":"3365_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1134\/S1070328423600547","volume":"49","author":"TA Antonenko","year":"2023","unstructured":"Antonenko TA, Gracheva YA, Zazdravnykh AV, Mazur DM, Shpakovsky DB, Lyssenko KA, et al. Synthesis and Antiproliferative Activity of New Copper, Cobalt, and Zinc Complexes with Abiraterone Acetate. Russ J Coord Chem. 2023;49(9):612\u201321. https:\/\/doi.org\/10.1134\/S1070328423600547.","journal-title":"Russ J Coord Chem"},{"key":"3365_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.molstruc.2019.04.068","volume":"1190","author":"RG Silveira","year":"2019","unstructured":"Silveira RG, Cunha BN, Ten\u00f3rio JC, de Aguiar DV, da Cruz SP, et al. A simple alternative to prodrug: the hydrochloride salt monohydrate of the prostate anticancer drug abiraterone. J Mol Struct. 2019;1190:165\u201370. https:\/\/doi.org\/10.1016\/j.molstruc.2019.04.068.","journal-title":"J Mol Struct"},{"issue":"4","key":"3365_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12040357","volume":"12","author":"U Gala","year":"2020","unstructured":"Gala U, Miller D, Williams RO III. Improved dissolution and pharmacokinetics of abiraterone through KinetiSol\u00ae enabled amorphous solid dispersions. Pharmaceutics. 2020;12(4): 357. https:\/\/doi.org\/10.3390\/pharmaceutics12040357.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3365_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40005-023-00654-7","volume":"54","author":"JW Tak","year":"2024","unstructured":"Tak JW, Kwon TK, Kim YI, Cho JH, Kim J, Kim JO. Development of abiraterone acetate tablets with enhanced oral bioavailability. J Pharm Investig. 2024;54(3):345\u201356. https:\/\/doi.org\/10.1007\/s40005-023-00654-7.","journal-title":"J Pharm Investig"},{"issue":"7","key":"3365_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1691\/ph.2021.0171","volume":"76","author":"H Zhou","year":"2021","unstructured":"Zhou H, Xu P, Sun Y. Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs. Die Pharmazie-An Int J Pharm Sci. 2021;76(7):308\u201312. https:\/\/doi.org\/10.1691\/ph.2021.0171.","journal-title":"Die Pharmazie-An Int J Pharm Sci"},{"key":"3365_CR24","doi-asserted-by":"publisher","first-page":"100077","DOI":"10.1016\/j.sintl.2020.100077","volume":"2","author":"S Das","year":"2021","unstructured":"Das S, Samanta A, Mondal S, Roy D, Nayak AK. Design and release kinetics of liposomes containing abiraterone acetate for treatment of prostate cancer. Sensors Int. 2021;2:100077. https:\/\/doi.org\/10.1016\/j.sintl.2020.100077.","journal-title":"Sensors Int"},{"issue":"3","key":"3365_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s13346-024-01657-z","volume":"15","author":"S Shah","year":"2025","unstructured":"Shah S, Famta P, Vambhurkar G, Sharma A, Mourya A, Srinivasarao DA, et al. Exploration of Abiraterone acetate loaded Nanostructured lipid carriers for bioavailability improvement and circumvention of fast-fed variability. Drug Deliv Transl Res. 2025;15(3):1074\u201391. https:\/\/doi.org\/10.1007\/s13346-024-01657-z.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"3365_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/08982104.2022.2069811","volume":"33","author":"R Katekar","year":"2023","unstructured":"Katekar R, Sen S, Riyazuddin M, Husain A, Garg R, Verma S, et al. Augmented experimental design for bioavailability enhancement: a robust formulation of abiraterone acetate. J Liposome Res. 2023;33(1):65\u201376. https:\/\/doi.org\/10.1080\/08982104.2022.2069811.","journal-title":"J Liposome Res"},{"issue":"2","key":"3365_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejpb.2011.03.019","volume":"79","author":"Y Li","year":"2011","unstructured":"Li Y, McClements DJ. Inhibition of lipase-catalyzed hydrolysis of emulsified triglyceride oils by low-molecular weight surfactants under simulated gastrointestinal conditions. Eur J Pharm Biopharm. 2011;79(2):423\u201331. https:\/\/doi.org\/10.1016\/j.ejpb.2011.03.019.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"3365_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/mnfr.201200720","volume":"57","author":"C Desmarchelier","year":"2013","unstructured":"Desmarchelier C, Tourniaire F, Pr\u00e9v\u00e9raud DP, Samson\u2010Kremser C, Crenon I, Rosilio V, et al. The distribution and relative hydrolysis of tocopheryl acetate in the different matrices coexisting in the lumen of the small intestine during digestion could explain its low bioavailability. Mol Nutr Food Res. 2013;57(7):1237\u201345. https:\/\/doi.org\/10.1002\/mnfr.201200720.","journal-title":"Mol Nutr Food Res"},{"key":"3365_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jconrel.2014.08.004","volume":"192","author":"IP de Sousa","year":"2014","unstructured":"de Sousa IP, Bernkop-Schn\u00fcrch A. Pre-systemic metabolism of orally administered drugs and strategies to overcome it. J Control Release. 2014;192:301\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2014.08.004.","journal-title":"J Control Release"},{"issue":"15","key":"3365_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154910","volume":"27","author":"X Li","year":"2022","unstructured":"Li X, Morita S, Yamada H, Koga K, Ota W, Furuta T, et al. Free linoleic acid and oleic acid reduce fat digestion and absorption in vivo as potent pancreatic lipase inhibitors derived from sesame meal. Molecules. 2022;27(15): 4910. https:\/\/doi.org\/10.3390\/molecules27154910.","journal-title":"Molecules"},{"key":"3365_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105466","volume":"153","author":"R Kumar","year":"2020","unstructured":"Kumar R, Sirvi A, Kaur S, Samal SK, Roy S, Sangamwar AT. Polymeric micelles based on amphiphilic oleic acid modified carboxymethyl chitosan for oral drug delivery of bcs class iv compound: intestinal permeability and pharmacokinetic evaluation. Eur J Pharm Sci. 2020;153: 105466. https:\/\/doi.org\/10.1016\/j.ejps.2020.105466.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3365_CR32","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s13346-024-01613-x","volume":"15","author":"RK Eid","year":"2025","unstructured":"Eid RK, Arafa MF, El Maghraby GM. Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin. Drug Deliv Transl Res. 2025;15(2):596\u2013608. https:\/\/doi.org\/10.1007\/s13346-024-01613-x.","journal-title":"Drug Deliv Transl Res"},{"issue":"8","key":"3365_CR33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3109\/03639045.2011.634811","volume":"38","author":"GM El Maghraby","year":"2012","unstructured":"El Maghraby GM, Elzayat EM, Alanazi FK. Development of modified in situ gelling oral liquid sustained release formulation of dextromethorphan. Drug Dev Ind Pharm. 2012;38(8):971\u20138. https:\/\/doi.org\/10.3109\/03639045.2011.634811.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"3365_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.2042-7158.1975.tb09378.x","volume":"27","author":"KA Khan","year":"1975","unstructured":"Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27(1):48\u20139. https:\/\/doi.org\/10.1111\/j.2042-7158.1975.tb09378.x.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"3365_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","volume":"30","author":"E Efstathiou","year":"2012","unstructured":"Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012;30(6):637\u201343. https:\/\/doi.org\/10.1200\/JCO.2010.33.7675.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3365_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/pcan.2014.8","volume":"17","author":"CJ Ryan","year":"2014","unstructured":"Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014;17(2):192\u20138. https:\/\/doi.org\/10.1038\/pcan.2014.8.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3365_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrurol.2013.274","volume":"11","author":"L Yin","year":"2014","unstructured":"Yin L, Hu Q. CYP17 inhibitors\u2014abiraterone, C17, 20-lyase inhibitors and multi-targeting agents. Nat Rev Urol. 2014;11(1):32\u201342. https:\/\/doi.org\/10.1038\/nrurol.2013.274.","journal-title":"Nat Rev Urol"},{"key":"3365_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","volume":"101","author":"A Thakur","year":"2018","unstructured":"Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother. 2018;101:211\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.067.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"3365_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/03639040500216428","volume":"31","author":"L Wei","year":"2005","unstructured":"Wei L, Sun P, Nie S, Pan W. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm. 2005;31(8):785\u201394. https:\/\/doi.org\/10.1080\/03639040500216428.","journal-title":"Drug Dev Ind Pharm"},{"issue":"5","key":"3365_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.apsb.2013.08.001","volume":"3","author":"K Prabhakar","year":"2013","unstructured":"Prabhakar K, Afzal SM, Surender G, Kishan V. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B. 2013;3(5):345\u201353. https:\/\/doi.org\/10.1016\/j.apsb.2013.08.001.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"3365_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060523","volume":"12","author":"D Van Staden","year":"2020","unstructured":"Van Staden D, Du Plessis J, Viljoen J. Development of a self-emulsifying drug delivery system for optimized topical delivery of clofazimine. Pharmaceutics. 2020;12(6): 523. https:\/\/doi.org\/10.3390\/pharmaceutics12060523.","journal-title":"Pharmaceutics"},{"key":"3365_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.smaim.2021.11.004","volume":"3","author":"K Zheng","year":"2022","unstructured":"Zheng K, Gu Q, Zhou D, Zhou M, Zhang L. Recent progress in surgical adhesives for biomedical applications. Smart Mater Med. 2022;3:41\u201365. https:\/\/doi.org\/10.1016\/j.smaim.2021.11.004.","journal-title":"Smart Mater Med"},{"issue":"6","key":"3365_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065064","volume":"24","author":"H Malektaj","year":"2023","unstructured":"Malektaj H, Drozdov AD, Christiansen JD. Swelling of homogeneous alginate gels with multi-stimuli sensitivity. Int J Mol Sci. 2023;24(6): 5064. https:\/\/doi.org\/10.3390\/ijms24065064.","journal-title":"Int J Mol Sci"},{"key":"3365_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jddst.2015.06.011","volume":"29","author":"GM El Maghraby","year":"2015","unstructured":"El Maghraby GM, Elsisi AE, Elmeshad GA. Development of liquid oral sustained release formulations of nateglinide: in vitro and in vivo evaluation. J Drug Deliv Sci Technol. 2015;29:70\u20137. https:\/\/doi.org\/10.1016\/j.jddst.2015.06.011.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"3365_CR45","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1021\/bm0501510","volume":"6","author":"Y Cao","year":"2005","unstructured":"Cao Y, Shen X, Chen Y, Guo J, Chen Q, Jiang X. pH-induced self-assembly and capsules of sodium alginate. Biomacromol. 2005;6(4):2189\u201396. https:\/\/doi.org\/10.1021\/bm0501510.","journal-title":"Biomacromol"},{"issue":"12","key":"3365_CR46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/03639040802032895","volume":"34","author":"S Gutsche","year":"2008","unstructured":"Gutsche S, Krause M, Kranz H. Strategies to overcome pH-dependent solubility of weakly basic drugs by using different types of alginates. Drug Dev Ind Pharm. 2008;34(12):1277\u201384. https:\/\/doi.org\/10.1080\/03639040802032895.","journal-title":"Drug Dev Ind Pharm"},{"key":"3365_CR47","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.ijbiomac.2021.05.174","volume":"182","author":"YH Li","year":"2021","unstructured":"Li YH, Wang YS, Zhao JS, Li ZY, Chen HH. A pH-sensitive curcumin loaded microemulsion-filled alginate and porous starch composite gels: characterization, in vitro release kinetics and biological activity. Int J Biol Macromol. 2021;182:1863\u201373. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.05.174.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"3365_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41538-023-00208-z","volume":"7","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zi Y, Shi C, Gong H, Zhang H, Wang X, et al. Tween emulsifiers improved alginate-based dispersions and ionic crosslinked milli-sized capsules. NPJ Sci Food. 2023;7(1): 33. https:\/\/doi.org\/10.1038\/s41538-023-00208-z.","journal-title":"NPJ Sci Food"},{"issue":"21","key":"3365_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222112022","volume":"22","author":"K Bialik-W\u0105s","year":"2021","unstructured":"Bialik-W\u0105s K, Pluta K, Malina D, Barczewski M, Malarz K, Mrozek-Wilczkiewicz A. The effect of glycerin content in sodium alginate\/poly (vinyl alcohol)-based hydrogels for wound dressing application. Int J Mol Sci. 2021;22(21): 12022. https:\/\/doi.org\/10.3390\/ijms222112022.","journal-title":"Int J Mol Sci"},{"key":"3365_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.foodres.2015.12.016","volume":"80","author":"SH Ching","year":"2016","unstructured":"Ching SH, Bansal N, Bhandari B. Rheology of emulsion-filled alginate microgel suspensions. Food Res Int. 2016;80:50\u201360. https:\/\/doi.org\/10.1016\/j.foodres.2015.12.016.","journal-title":"Food Res Int"},{"issue":"1","key":"3365_CR51","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.carbpol.2009.11.020","volume":"80","author":"R Pamies","year":"2010","unstructured":"Pamies R, Schmidt RR, Mart\u00ednez MD, de la Torre JG. The influence of mono and divalent cations on dilute and non-dilute aqueous solutions of sodium alginates. Carbohydr Polym. 2010;80(1):248\u201353. https:\/\/doi.org\/10.1016\/j.carbpol.2009.11.020.","journal-title":"Carbohydr Polym"},{"key":"3365_CR52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.colsurfb.2014.11.022","volume":"126","author":"AG Agrawal","year":"2015","unstructured":"Agrawal AG, Kumar A, Gide PS. Self emulsifying drug delivery system for enhanced solubility and dissolution of glipizide. Colloids Surf B Biointerfaces. 2015;126:553\u201360. https:\/\/doi.org\/10.1016\/j.colsurfb.2014.11.022.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"7","key":"3365_CR53","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02085-9","volume":"22","author":"P Gao","year":"2021","unstructured":"Gao P, Jiang Z, Luo Q, Mu C, Cui M, Yang X. Preparation and evaluation of self-emulsifying drug delivery system (SEDDS) of cepharanthine. AAPS PharmSciTech. 2021;22(7): 245. https:\/\/doi.org\/10.1208\/s12249-021-02085-9.","journal-title":"AAPS PharmSciTech"},{"key":"3365_CR54","doi-asserted-by":"publisher","first-page":"105821","DOI":"10.1016\/j.jddst.2024.105821","volume":"97","author":"M El-Araby","year":"2024","unstructured":"El-Araby M, El-Gizawy SA, Ashmawy SM, El Maghraby GM. Cinnamon oil-based self-emulsifying system for augmented dissolution and hypoglycemic efficacy of gliquidone. J Drug Deliv Sci Technol. 2024;97:105821. https:\/\/doi.org\/10.1016\/j.jddst.2024.105821.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"3365_CR55","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jmbbm.2011.04.002","volume":"4","author":"JL Bron","year":"2011","unstructured":"Bron JL, Vonk LA, Smit TH, Koenderink GH. Engineering alginate for intervertebral disc repair. J Mech Behav Biomed Mater. 2011;4(7):1196\u2013205. https:\/\/doi.org\/10.1016\/j.jmbbm.2011.04.002.","journal-title":"J Mech Behav Biomed Mater"},{"issue":"3","key":"3365_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.partic.2010.12.002","volume":"9","author":"ES Chan","year":"2011","unstructured":"Chan ES, Lim TK, Voo WP, Pogaku R, Tey BT, Zhang Z. Effect of formulation of alginate beads on their mechanical behavior and stiffness. Particuology. 2011;9(3):228\u201334. https:\/\/doi.org\/10.1016\/j.partic.2010.12.002.","journal-title":"Particuology"},{"key":"3365_CR57","doi-asserted-by":"publisher","unstructured":"Shukla S, Jain D, Verma K. Formulation and in vitro characterization of alginate microspheres loaded with diloxanide furoate for colon-specific drug delivery. Asian J Pharm (AJP). 2010;4(4). https:\/\/doi.org\/10.22377\/ajp.v4i4.229.","DOI":"10.22377\/ajp.v4i4.229"},{"issue":"3","key":"3365_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40005-017-0304-1","volume":"48","author":"VC Patole","year":"2018","unstructured":"Patole VC, Pandit AP. Mesalamine-loaded alginate microspheres filled in enteric coated HPMC capsules for local treatment of ulcerative colitis: in vitro and in vivo characterization. J Pharm Investig. 2018;48(3):257\u201367. https:\/\/doi.org\/10.1007\/s40005-017-0304-1.","journal-title":"J Pharm Investig"},{"issue":"18","key":"3365_CR59","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1016\/j.biomaterials.2004.09.062","volume":"26","author":"Z Li","year":"2005","unstructured":"Li Z, Ramay HR, Hauch KD, Xiao D, Zhang M. Chitosan\u2013alginate hybrid scaffolds for bone tissue engineering. Biomaterials. 2005;26(18):3919\u201328. https:\/\/doi.org\/10.1016\/j.biomaterials.2004.09.062.","journal-title":"Biomaterials"},{"issue":"6","key":"3365_CR60","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/bip.20509","volume":"82","author":"L Baruch","year":"2006","unstructured":"Baruch L, Machluf M. Alginate\u2013chitosan complex coacervation for cell encapsulation: effect on mechanical properties and on long\u2010term viability. Biopolymers. 2006;82(6):570\u20139. https:\/\/doi.org\/10.1002\/bip.20509.","journal-title":"Biopolymers"},{"key":"3365_CR61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2605.1980.tb00140.x","volume":"3","author":"LH Heywood","year":"1980","unstructured":"Heywood LH. Testosterone levels in the male laboratory rat: variation under experimental conditions. Int J Androl. 1980;3:519\u201329. https:\/\/doi.org\/10.1111\/j.1365-2605.1980.tb00140.x.","journal-title":"Int J Androl"},{"issue":"1","key":"3365_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2009.10.005","volume":"142","author":"F Buyukozturk","year":"2010","unstructured":"Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. J Control Release. 2010;142(1):22\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2009.10.005.","journal-title":"J Control Release"},{"issue":"1-2","key":"3365_CR63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijpharm.2017.02.036","volume":"521","author":"G Mamadou","year":"2017","unstructured":"Mamadou G, Charrueau C, Dairou J, Nzouzi NL, Eto B, Ponchel G. Increased intestinal permeation and modulation of presystemic metabolism of resveratrol formulated into self-emulsifying drug delivery systems. Int J Pharm. 2017;521(1\u20132):150\u20135. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.02.036.","journal-title":"Int J Pharm"},{"issue":"6","key":"3365_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28062827","volume":"28","author":"A Mahmood","year":"2023","unstructured":"Mahmood A, Khan L, Ijaz M, Nazir I, Naseem M, Tahir MA, et al. Enhanced intestinal permeability of cefixime by self-emulsifying drug delivery system: in-vitro and ex-vivo characterization. Molecules. 2023;28(6): 2827. https:\/\/doi.org\/10.3390\/molecules28062827.","journal-title":"Molecules"},{"issue":"5","key":"3365_CR65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0928-0987(02)00051-9","volume":"15","author":"CM O\u2019Driscoll","year":"2002","unstructured":"O\u2019Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15(5):405\u201315. https:\/\/doi.org\/10.1016\/S0928-0987(02)00051-9.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3365_CR66","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1166\/jnn.2015.9248","volume":"15","author":"HY Cho","year":"2015","unstructured":"Cho HY, Choi JH, Oh IJ, Lee YB. Self-emulsifying drug delivery system for enhancing bioavailability and lymphatic delivery of tacrolimus. J Nanosci Nanotechnol. 2015;15(2):1831\u201341. https:\/\/doi.org\/10.1166\/jnn.2015.9248.","journal-title":"J Nanosci Nanotechnol"},{"key":"3365_CR67","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S214883","author":"H Liao","year":"2019","unstructured":"Liao H, Gao Y, Lian C, Zhang Y, Wang B, Yang Y, et al. Oral absorption and lymphatic transport of baicalein following drug\u2013phospholipid complex incorporation in self-microemulsifying drug delivery systems. Int J Nanomed. 2019. https:\/\/doi.org\/10.2147\/IJN.S214883.","journal-title":"Int J Nanomed"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03365-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:52:16Z","timestamp":1780390336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03365-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03365-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This investigation was conducted on male albino rats. Animal treatment and housing were based on the National Institute of Health guide for the care and manipulation of laboratory animals. The protocol of this investigation was initiated after approval from the ethical committee of Faculty of Pharmacy, Tanta University (approval number: TP\/RE\/3\/25 p-04).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"No conflict of interest reported by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interest"}}],"article-number":"158"}}